Search Results - "Barakat, Eman M"

Hepatocellular carcinoma in Egypt： A single center study over a decade by el-Zayadi, Abdel-Rahman, Badran, Hanaa M, Barakat, Eman M F, Attia, Mohy el-Deen, Shawky, Sherine, Mohamed, Mostafa K, Selim, Osaima, Saeid, Ahmed

“…AIM： To identify the trend, possible risk factors and any pattern change of hepatocellular carcinoma （HCC） in Egypt over a decade. METHODS： All HCC patients…”
Get full text

Prognostic Significance of E-cadherin Expression and Peripheral Blood Micrometastasis in Gastric Carcinoma Patients by Saad, Abeer A., Awed, Nahla M., Abd Elkerim, Nashwa N. A., EL-Shennawy, Dina, Alfons, Marian A., Elserafy, Mohamed E., Darwish, Yaser W., Barakat, Eman M. F., Ezz-Elarab, Sahar S.

“…Background The primary objective is to evaluate the prognostic value of E-cadherin (E-cad) expression and peripheral blood micrometastasis (PBMM) in gastric…”
Get full text

Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study by El-Zayadi, Abdel-Rahman, Attia, Mohy, Barakat, Eman M F, Badran, Hanaa M, Hamdy, Hassan, El-Tawil, Ahmed, El-Nakeeb, Adham, Selim, Osaima, Saied, Ahmed

“…Currently, pegylated interferon is the most effective therapy for hepatitis C but its cost is out of reach of most patients in the developing countries. The…”
Get full text

Reliability of Transient Elastography as a non-Invasive Technique for Detection of Fibrosis in Budd Chiari Syndrome Patients after Endovascular Intervention by Montasser, Mohammed F, Barakat, Eman M, Ghazy, Mohamed S, Abdelhakam, Sara M, Ebada, Hend E, Elganzory, Ahmed T

“…Abstract Aim of the work To test the reliability of fibroscan in detection of fibrosis in patients with Budd Chiari syndrome before and after endovascular…”
Get full text

Cerebrospinal fluid Lipocalin 2 as a marker for the detection of acute bacterial meningitis by Barakat, Eman M., Zaky, Doaa Z., Abdelhamid, Mohamed S., Shaaban, Mentallah A., Haddad, Hegazy A.

Get full text

Response of Hepatitis C Genotype-4 Naïve Patients to 24 Weeks of Peg-Interferon-α2b Ribavirin or Induction-Dose Interferon-α2b Ribavirin Amantadine: A Non-Randomized Controlled Study by EL-ZAYADI, Abdel-Rahman, ATTIA, Mohy, BARAKAT, Eman M. F, BADRAN, Hanaa M, HAMDY, Hassan, EL-TAWIL, Ahmed, EL-NAKEEB, Adham, SELIM, Osaima, SAIED, Ahmed

Get full text

Egyptian Society of Liver Cancer Recommendation Guidelines for the Management of Hepatocellular Carcinoma by Omar, Ashraf, Kaseb, Ahmed, Elbaz, Tamer, El-Kassas, Mohamed, El Fouly, Amr, Hanno, Abdel Fatah, El Dorry, Ahmed, Hosni, Ahmed, Helmy, Amr, Saad, Amr S, Alolayan, Ashwaq, Eysa, Basem Elsayed, Hamada, Emad, Azim, Hamdy, Khattab, Hany, Elghazaly, Hesham, Tawfik, Hesham, Ayoub, Hisham, Khaled, Hussein, Saadeldin, Ibtessam, Waked, Imam, Barakat, Eman M F, El Meteini, Mahmoud, Hamed Shaaban, Mohamed, EzzElarab, Mohamed, Fathy, Mohamed, Shaker, Mohamed, Sobhi, Mohamed, Shaker, Mohamed Kamal, ElGharib, Mohamed, Abdullah, Mohammed, Mokhtar, Mohesn, Elshazli, Mostafa, Heikal, Omar Mohamed Khaleil, Hetta, Osama, ElWakil, Reda Mahmoud, Abdel Wahab, Sameh, Eid, Samir Shehata, Rostom, Yousri

“…Globally, hepatocellular carcinoma (HCC) is the fourth most common cause of death from cancer. The prevalence of this pathology, which has been on the rise in…”
Get full text

Innovative approaches to metabolic dysfunction-associated steatohepatitis diagnosis and stratification by Matboli, Marwa, Hamady, Shaimaa, Saad, Maha, Khaled, Radwa, Khaled, Abdelrahman, Barakat, Eman MF, Sayed, Sayed Ahmed, Agwa, SaraH.A., Youssef, Ibrahim

“…The global rise in Metabolic dysfunction-associated steatotic liver disease (MASLD)/Metabolic dysfunction-associated steatohepatitis (MASH) highlights the…”
Get full text

Response of Hepatitis C Genotype-4 Naive Patients to 24 Weeks of Peg-Interferon-a2b/Ribavirin or Induction-Dose Interferon-a2b/Ribavirin/Amantadine: A Non-Randomized Controlled Study by El-Zayadi, Abdel-Rahman, Attia, Mohy, Barakat, Eman M F, Badran, Hanaa M, Hamdy, Hassan, El-Tawil, Ahmed, El-Nakeeb, Adham, Selim, Osaima, Saied, Ahmed

“…BACKGROUND AND AIM:Currently, pegylated interferon is the most effective therapy for hepatitis C but its cost is out of reach of most patients in the…”
Get full text

Response of Hepatitis C Genotype-4 Naïve Patients to 24 Weeks of Peg-Interferon-[alpha]2b/Ribavirin or Induction-Dose Interferon-[alpha]2b/Ribavirin/Amantadine: A Non-Randomized Controlled Study by El-zayadi, Abdel-rahman, Attia, Mohy, Barakat, Eman M F, Badran, Hanaa M, Hamdy, Hassan, El-tawil, Ahmed, El-nakeeb, Adham, Selim, Osaima, Saied, Ahmed

“…BACKGROUND AND AIM:Currently, pegylated interferon is the most effective therapy for hepatitis C but its cost is out of reach of most patients in the…”
Get full text

Response of Hepatitis C Genotype-4 Naive Patients to 24 Weeks of Peg-Interferon- alpha 2b-Ribavirin or Induction-Dose Interferon- alpha 2b-Ribavirin-Amantadine: A Non-Randomized Controlled Study by El-Zayadi, Abdel-Rahman, Attia, Mohy, Barakat, Eman MF, Badran, Hanaa M, Hamdy, Hassan, El-Tawil, Ahmed, El-Nakeeb, Adham, Selim, Osaima, Said, Ahmed

“…BACKGROUND AND AIMCurrently, pegylated interferon is the most effective therapy for hepatitis C but its cost is out of reach of most patients in the developing…”
Get full text